clinical_dev

Clinical Development Pathway

Incannex is a cannabinoid and psychedelic compound medicine development company undertaking six clinical programs guided by our medical advisory board. These 6 programs are targeting conditions for patients with unmet medical needs. This means we have the ability to help billions of people around the planet. The potential is limitless.

Development Program
Pre-Discovery
Discovery
Pre-Clinical
Phase 1
Phase 2A
Phase 2B
Phase 3
IHL – 42X – OSA IHL-42X is a novel cannabinoid combination product for treatment of Obstructive Sleep Apnoea (OSA).
70%
PSI-GAD Incannex are developing a psilocybin assisted psychotherapy system for treatment of Generalised Anxiety Disorder (GAD).
70%
IHL-675A Lung Inflammation IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including inflammatory lung diseases such as COPD, asthma and ARDS.
61.5%
IHL-675A Rheumatoid Arthritis IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including rheumatoid arthritis.
61.5%
IHL-675A Inflammatory Bowel Disease IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including inflammatory bowel disease.
61.5%
IHL-216A TBI IHL-216A is a novel cannabinoid combination product for treatment of Traumatic Brain Injury (TBI).
45%

US$110 billion potential.

The combined annual global market size of the indications we are targeting is over US$110 billion, which is derived from the total addressable market for the treatment of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and GAD. Success in the clinical development programmes will not only provide benefit to patients suffering from untreated medical conditions, but also significant economic potential for shareholders.

circle_element;

Subscribe

Stay up to date with Incannex’s research and development program.